SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ma J, Mai HQ, Hong MH, et al. Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations? Int J Radiat Oncol Biol Phys. 2001;50:11811189.
  • 2
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup Study 0099. J Clin Oncol. 1998;16:13101317.
  • 3
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients (PTS) with advanced nasopharyngeal cancer (NPC). Intergroup (SWOG 8892, RTOG 8817, ECOG 2388) phase III study: progress report [abstract]. J Clin Oncol. 1998;17:385. Abstract 1483.
  • 4
    Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of 2 phase III trials. J Clin Oncol. 2005;23:11181124.
  • 5
    Marks JE, Philips JL, Menck HR. The national cancer data base report on the relationship of race and national origin to the histology of race and national origin to the histology of nasopharyngeal carcinoma. Cancer. 1998;83:582588.
  • 6
    Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:67306738.
  • 7
    Wee J. Nasopharyngeal Cancer Workgroup—the past, the present and the future. Ann Acad Med Singapore. 2008;37:606614.
  • 8
    Lee AW, Lau WH, Tung SY, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:69666975.
  • 9
    Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102:11881198.
  • 10
    Chen Y, Liu MZ, Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy to radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of China. Int J Radiat Oncol Biol Phys. 2008;71:13561364.
  • 11
    Fleming ID, Cooper JS, Henson DE, et al. eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven, Inc.; 1997.
  • 12
    Ma J, Mai HQ, Hong MH, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19:13501357.
  • 13
    Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207214.
  • 14
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:13411346.
  • 15
    Chua DT, Sham JS, Au GK, et al. Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. Int J Radiat Oncol Biol Phys. 2002;53:334343.
  • 16
    Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional 2-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011;80:661668.
  • 17
    Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002;20:20382044.
  • 18
    Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536539.
  • 19
    Gregg RW, Matshela MJ, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurological tissue and morphological evidence of toxicity. J Clin Oncol. 1992;10:795803.
  • 20
    Chan SH, Ng WT, Kam KL, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol Phys. 2009;73:13351342.
  • 21
    Kwong DL, Wei WI, Sham JS, et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Radiat Oncol Biol Phys. 1996;36:281289.
  • 22
    Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631637.
  • 23
    Zhang L, Zhao C, Peng PJ, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol. 2005;23:84618468.
  • 24
    Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of 8 randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:4756.
  • 25
    Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004;22:46044612.
  • 26
    Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163171.